This comprehensive case study explores Kymanox’s approach to orphan drug reformulation and accelerated development through Quality by Design (QbD) principles and innovative packaging solutions. Our team of Subject Matter Experts (SMEs) collaborated closely with virtual pharmaceutical stakeholders to implement measurable improvements across formulation optimization, custom packaging development, Contract Development Manufacturing Organization (CDMO) management, and 505(b)(2) regulatory strategy for pediatric neurological syndrome treatment serving critically underserved patient population.
CHALLENGE
SOLUTION
RESULTS
- Mid-cap virtual pharmaceutical client required orphan drug development for debilitating pediatric neurological syndrome transitioning from liquid to powder for oral solution format.
- Formulation development and packaging challenges needed resolution ensuring pediatric patient compliance, dosing accuracy, and product stability meeting tight development timelines.
- Custom packaging solutions essential accommodating large dose sizes and thermolabile Active Pharmaceutical Ingredient (API) characteristics while maintaining product integrity and ease of use.
- Accelerated development pathway critical enabling timely market access for pediatric patients with limited treatment options and severe unmet medical needs.
- Applied comprehensive QbD principles optimizing powder mixing processes, ensuring content uniformity, maintaining API stability, and enhancing powder flowability.
- Developed innovative custom packaging components and selected specialized foil materials accommodating large dose sizes and protecting thermolabile drug substance.
- Employed iterative process adjustments, creative engineering solutions, and rigorous data-driven decision-making overcoming complex formulation and packaging challenges.
- Managed complete project lifecycle from CDMO selection through commercial production achieving timely 505(b)(2) regulatory submission.
- Identified significant cost efficiencies running parallel pre-formulation studies with multiple flavor options, simultaneous formulation development and clinical taste assessments.
- Leveraged advanced analytics and parallel workflow strategies enabling faster project execution and accelerated decision-making throughout development.
- Successfully reduced development timelines by six (6) months through efficient parallel execution and strategic planning exceeding industry standard development speeds.
- Achieved substantial 25% cost reduction through innovative parallel development approaches, optimized resource allocation, and efficient CDMO management.
- Delivered high-quality orphan drug product with innovative packaging solutions meeting stringent regulatory requirements and ensuring pediatric patient compliance.
- Successfully transitioned product to stable powder format within twelve (12) months exceeding client expectations and ensuring timely market entry for underserved patients.
- Established scalable commercial manufacturing process supporting long-term product supply and pediatric patient access to life-changing therapy.